Chemotherapeutics
Active Ingredient in Arestin
1.0 mg Minocycline
Expected probe depth reduction after oral hygiene alone
0.5mm
Percentage of "acceptable" bleeding at the re-eval
<30% of initial sites
4910
Perio Maint
Oral rinse FDA approved to treat Gingivitis
CHX
Systemic drug of choice for aggressive perio
Tetracycline
Probe depth reduction expected after NSPT in a 4-6mm pocket
1.0mm
Optimum time to wait for a re-eval
4-6 weeks
4341
SRP 4+ Teeth
Main ingredient in cosmetic rinses
Quaternary Ammonium Compounds
Systemic agent that can cause clostridium difficilie (c. diff)
Clindamycin
Attachment gain expected after NSPT in a 4-6mm pocket
0.5mm
Refractory disease
Patient fails to respond to periodontal therapy
4342
SRP 1-3 Teeth
Mechanism of action of oxidizing rinses
Effervescence--produces a gaseous oxygen where anaerobic bacteria cannot live
Bacteria targeted by Metronidazole
Anaerobic bacteria and spirochetes
Expected probe depth reduction after NSPT in 6mm+ pockets
2mm
People who believe what THEY do will affect their health.
Internal locus of control
4355
FMD
Reduces plaque 25-80%
CHX
3 criteria for an effective chemotherapuetic agent
Ability to reach disease
Delivered at bacteriostatic or bactericidal concentrations
Remain in place long enough to be effective
Level of bone loss needed to present radiographically
30-50%
Prognosis of a tooth with Grade II Furcation and moderate attachment loss
Poor
4346
Scaling in the Presence of Gingival Inflammation
The rinse best used to treat necrotizing perio (NP)
Povidone Iodine